On May 31, 2019 AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, reported that it will be presenting at the upcoming Bio International Convention taking place June 3-6 in Philadelphia, Pennsylvania (Press release, AIVITA Biomedical, MAY 31, 2019, View Source [SID1234536736]). AIVITA CEO Dr. Hans Keirstead will deliver a corporate presentation highlighting the company’s clinical and commercial programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BIO International Convention is an annual event hosting more than 16,000 attendees from around the globe seeking opportunities in partnering, education, and networking with global biotech and pharma leaders. Details of the company presentation are as follows:

Date: Monday June 3, 2019
Time: 2:15 PM EDT
Location: Pennsylvania Convention Center, Philadelphia, Theater 3

In his presentation Dr. Keirstead will highlight new predictive efficacy clinical efficacy data from AIVITA’s ongoing 8-center Phase 2 immunotherapy clinical trial in patients with glioblastoma. The trial is investigating AIVITA’s platform cancer technology, a next generation immunotherapy targeting the tumor-initiating stem cell. Dr. Keirstead will also share recent developments and international distribution partnerships for its ROOT of SKIN line of consumer skincare products, all of the proceeds of which support the treatment of women with ovarian cancer.